Add Yahoo as a preferred source to see more of our stories on Google. UCLA scientists created AlloCAR70-NKT, a ready-to-use immune cell therapy that targets kidney cancer from multiple angles—without ...

Mesothelin-targeted CAR-NKT cells leveraged three recognition mechanisms, potentially limiting antigen escape and immunoediting compared with single-pathway CAR-T constructs. Complete tumor ...

Chimeric antigen receptor, or CAR, therapy is no longer just a cancer story. This review shows how the field is expanding beyond conventional CAR-T cells into a wider family of engineered cell ...

UCLA researchers have developed a CAR-NKT cell therapy that has shown to be more effective than current immunotherapies at fighting cancer in tumor samples from late-stage triple-negative breast ...

Glioblastoma, the most aggressive and lethal form of brain cancer in adults, has long evaded effective treatment due to its resistance to standard therapies, including surgical resection, radiation, ...

Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market LA JOLLA, CA, ...

Despite decades of research, treatment for many diseases still focuses on the management of symptoms. Regenerative medicine aims to use cell and gene therapy, and tissue engineering, to treat the root ...

Researchers at UCLA have developed a powerful new weapon in the battle against kidney cancer. Instead of relying on treatments tailored to each patient, this innovation uses specially engineered ...

BioWorld - Thursday, October 23, 2025 Breaking News: Trump administration impacts continue to roil the life sciences sector See today's BioWorld Science Home » Study evaluates allogeneic ...

Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market LA JOLLA, CA, ...